Results from a large scale trial have found that obesity drug Wegovy can cut the risk of cardiovascular events by 20 percent.
“Our approach has allowed us to build a comprehensive atlas mapping the associations of GLP-1RA spanning all organ systems,” he said. “The study’s results provide insights into some known and previously unrecognized benefits and risks of GLP-1RA that may be useful to inform clinica...
Acosta said the researchers previously saw a similar pattern in patients taking the weight-loss drug liraglutide, which is marketed under the names Victoza and Saxenda by Novo Nordisk. While patients without the “hungry gut” genes did lose some weight on Wegovy, they might be able to lose si...